Last update: April 2, 2015
Poorly safe. Evaluate carefully.
Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives).
Read the Comment.
At latest update, relevant published data on excretion into breast milk were not found.
Because of a high protein-binding capacity, a significant excretion into breast milk is unlikely.
However, it is one among the Sartan drugs (ARA-II type) with the longest half-life and highest oral bioavailability. The latter properties make it less convenient for use while breastfeeding.
Reportedly, a newborn infant appeared with transient renal failure (kidney malfunction) whose mother had taken this medication during pregnancy.
Until more data on this medication is available safer alternative drugs are preferred especially in premature babies or during the neonatal period.
Should an ARA-II medication (Sartan type) be necessary, the associated risk may be decreased by choosing the one with a favorable pharmacokinetics (shorter half-life elimination time and lower bioavailability) like Eprosartan and Losartan.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.